Testoluten

In simple words

Testoluten is a complex of short peptides from the testes of young animals, developed by the Khavinson school. It is considered a support for testicular function, but there are no direct scientific publications about it.

What this molecule is

A complex of di-/tri-/tetrapeptides from the testes of young animals. The exact sequence is a proprietary composition. IBG RAS, Khavinson.

Why it is studied

A bioregulatory peptide complex for supporting testicular function and spermatogenesis. Based on Khavinson's concept of organ-specific peptide geroprotection. There are NO publications in PubMed under this name — the data are extrapolated from the general IBG RAS bioregulator program.

How it works

According to Khavinson's concept: short peptides from the testes → DNA promoters of testicular cells → ↑expression of spermatogenesis and steroidogenesis genes (like epigenetic "keys"). The mechanism has not been confirmed by independent RCTs.

Doses used in studies

In bioregulator programs, 1–2 capsules per day with meals were used for a 30-day course, with repeat courses 2–4 times per year. Not a medicinal product.

Combined with in studies

• Prostatoluten — prostate bioregulator
• Epitalon — geroprotection
• Testosterone replacement therapy — Does NOT replace it in confirmed hypogonadism

Level of evidence

Level D Cells and reviews. Only cell studies (in vitro), theory, or reviews. The earliest stage. No direct publications under the name 'Testoluten'. Data are extrapolated.

Important to know

🔴 There are no PubMed publications under the trade name 'Testoluten'. Not a medicine. No independent RCTs have been conducted. Does not replace medical treatment of hypogonadism.

Studies in PubMed

1. [Peptide bioregulators: the new class of geroprotectors. Communication 1. Results of experimental studies]. (Adv Gerontol, 2012)
2. [Peptide bioregulators: the new class of geroprotectors. Message 2. Clinical studies results]. (Adv Gerontol, 2013)
3. [Peptide geroprotector application for treatment of elderly and senile patients with prostatic hyperplasia]. (Adv Gerontol, 2013)
4. Peptide bioregulation of aging: results and prospects. (Biogerontology, 2010)
5. [The use of bioregulatory peptides in the treatment of men with benign prostatic hyperplasia and chronic prostatitis]. (Urologiia, 2021)
6. Peptide Regulation of Cell Differentiation. (Stem Cell Rev Rep, 2020)